Stockscreener 앱 받기
1.14
0.87%
-0.01
시간 외 거래:
1.19
0.05
+4.39%
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
BlackRock (NYSE: BLK) discloses 5.4% ownership of ADC Therapeutics (ADCT) - Stock Titan
Orbimed Advisors LLC Has $4.94 Million Stock Position in ADC Therapeutics SA $ADCT - MarketBeat
TradingKey - TradingKey
ADCT|ADC Therapeutics SA|Price:1.145|Chg%:-0.005 - TradingKey
ADC Therapeutics SA (ADCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ADC Therapeutics SA (ADCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ADCT|ADC Therapeutics SA|Price:1.150|Chg%:-0.045 - TradingKey
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Finan - GuruFocus
ADC Therapeutics SA (NYSE:ADCT) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
ADC Therapeutics SA (ADCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ADC Therapeutics stock stabilizes as Zynlonta revenue supports biotech valuation - Ad-hoc-news.de
ADC Therapeutics stock trades steady as revenue grows and liquidity plan develops - Ad-hoc-news.de
ADC Therapeutics (NYSE:ADCT) Shares Down 6.3%Time to Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA - The National Law Review
ADC Therapeutics (ADCT) Holds Steady at $1.35 as Key Support and Resistance Levels NarrowPairs Trade - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeut - The National Law Review
ADC Therapeutics (ADCT) Holds Near Support Amid Slight Decline – Technical AnalysisVWAP Breakout - dars.gov.et
ADC Therapeutics (ADCT) Holds Near Support After Marginal DeclineBreadth Thrust - dars.gov.et
Press Release: ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates - Moomoo
Biocytogen and Whitehawk partner to develop ADCs - Pharmaceutical Technology
The ZYNLONTA therapy. ADCT targets US lymphoma patients with a focused antibody-drug treatment - ad-hoc-news.de
Novartis finally enters the ADC field with an unprecedented technology - Agefi.com
ADC Therapeutics Grants One-Time Retention Awards to Executives - TipRanks
ADC Therapeutics (ADCT) CMO awarded 213,900 RSUs, raising holdings to 896,317 shares - Stock Titan
ADC Therapeutics (ADCT) grants 221,100 RSUs to Chief Legal Officer - Stock Titan
ADC Therapeutics (ADCT) grants CFO 203,700 RSUs as equity award - Stock Titan
ADC Therapeutics (ADCT) CEO receives 675,000 RSU equity award in Form 4 filing - Stock Titan
Executive retention awards approved at ADC Therapeutics (NYSE: ADCT) - Stock Titan
ADC Therapeutics Announces New Employee Inducement Grant - AOL.com
ADC Therapeutics Completes Enrollment in LOTIS-7, Advancing ZYNLONTA-Glofitamab Combination in DLBCL - BioPharm International
ADC Therapeutics completes LOTIS-7 trial enrollment - grafa.com
ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study - marketscreener.com
ADC Therapeutics completes enrollment in LOTIS-7 trial - Investing.com
ADC Therapeutics completes enrollment in LOTIS-7 trial By Investing.com - Investing.com Nigeria
ADC Therapeutics ends enrollment in ZYNLONTA combo trial for lymphoma - Stock Titan
ADC Therapeutics updates trial strategy, shares react to oncology shift - ad-hoc-news.de
ETFs Investing in ADC Therapeutics Ltd Stocks - TradingView
ADC Therapeutics SA(NYSE: ADCT) added to Russell 2000 Value Benchmark - marketscreener.com
ADC Therapeutics SA(NYSE: ADCT) added to Russell Microcap Value Benchmark Index - marketscreener.com
ADCT stock plunges on safety concerns despite positive lymphoma data - MSN
ADC Therapeutics SA(NYSE: ADCT) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
ADCT Q3 2020 Earnings Call - BigGo ファイナンス
ADC Therapeutics SA(NYSE: ADCT) added to Russell 3000 Value Benchmark - marketscreener.com
Enterprise value to revenue forward of ADC Therapeutics SA – NYSE:ADCT - TradingView
ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Analyst Views - Yahoo Finance
Enterprise value to EBIT forward of ADC Therapeutics SA – NYSE:ADCT - TradingView
Enterprise value to EBITDA forward of ADC Therapeutics SA – NYSE:ADCT - TradingView
Price to earnings forward of ADC Therapeutics SA – NYSE:ADCT - TradingView
ADCT News | ADC THERAPEUTICS SA (NYSE:ADCT) - ChartMill
Price to sales forward of ADC Therapeutics SA – NYSE:ADCT - TradingView
ADC Therapeutics Ltd Actuals & Estimates (NYSE:ADCT) - TradingView
ADCT Forecast — Price Target — Prediction for 2027 - TradingView
ADC Therapeutics Announces ZYNLONTA-Focused Strategic Reorganization - The Globe and Mail
ADC Therapeutics launches restructuring around ZYNLONTA - grafa.com
ADC Therapeutics Announces 17% Workforce Reduction and Strategic Reorganization to Boost ZYNLONTA® Growth and Regulatory Milestones - Minichart
Bronstein, Gewirtz & Grossman, LLC (ADCT) Investigation: Bronstei - The National Law Review
ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details - Stocktwits
ADC Therapeutics plans 17% workforce cut to save ~$10M annually, $3M one-time charges - TradingView
ADC Therapeutics (NYSE: ADCT) trims workforce 17% to back ZYNLONTA trials and extend cash runway - Stock Titan
0.30%
2.01%
자본화:
|
볼륨(24시간):